25947-14-2

Basic information

• Product Name: 1-Phthalazineacetic acid, 3,4-dihydro-4-oxo-, Methyl ester
• Synonyms: 1-Phthalazineacetic acid, 3,4-dihydro-4-oxo-, Methyl ester;Methyl 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetate
• CAS NO: 25947-14-2
• Molecular Formula: C₁₁H₁₀N₂O₃
• Molecular Weight: 218.2087
• Mol File: 25947-14-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• PKA: 11.60±0.40(Predicted)
• CAS DataBase Reference: 1-Phthalazineacetic acid, 3,4-dihydro-4-oxo-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Phthalazineacetic acid, 3,4-dihydro-4-oxo-, Methyl ester(25947-14-2)
• EPA Substance Registry System: 1-Phthalazineacetic acid, 3,4-dihydro-4-oxo-, Methyl ester(25947-14-2)

Safety Data

• Hazardous Substances Data: 25947-14-2(Hazardous Substances Data)

Usage

Chemical Class

Phthalazines, organic compounds containing a phthalazine moiety.

Structure

1-Phthalazineacetic acid, 3,4-dihydro-4-oxo-, Methyl ester.

Activity

Potent inhibitor of hypoxia-inducible factor-1 (HIF-1) activation, a key regulator of tumor adaptation to microenvironmental stress.

抗癌能力

Displays potential anticancer activity through its ability to inhibit angiogenesis and reduce tumor growth.

抗炎能力

Possesses anti-inflammatory properties, making it a potential candidate for the development of therapeutic agents for cancer and inflammatory diseases.

Upstream product

• 25947-11-9 1,2-Dihydro-1-oxophthalazin-4-ylacetic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 85-44-9 phthalic anhydride 
• 4743-57-1 phthalidyliden-acetic acid 

Downstream Products

• 1316307-92-2 methyl 2-(3-((3-(4-bromo-3-fluorophenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-94-4 methyl 2-(3-((3-(1-benzylpiperidin-4-yl)-4,5-dihydro-isoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-95-5 methyl 2-(3-((3-(2-hydroxyphenyl)-4,5-dihydro-isoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-85-3 methyl 3-methoxy-2-(4-oxo-3-((3-phenyl-4,5-dihydroisoxazol-5-yl)methyl)-3,4-dihydrophthalazin-1-yl)acrylate 
• 1316307-86-4 methyl 2-(3-((3-(4-chlorophenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-87-5 methyl 2-(3-((3-(4-fluorophenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-3-methoxyacrylate 
• 1316307-88-6 methyl 3-methoxy-2-(3-((3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acrylate 
• 1316307-89-7 methyl 2-(3-((3-(3,4-dimethoxyphenyl)-4,5-dihydro-isoxazol-5-yl)methyl)-4-oxo-3,4-dihydro phthalazin-1-yl)-3-methoxyacrylate 
• 1316307-90-0 methyl 2-(3-((3-(3-(4-fluorophenoxy)phenyl)-4,5-dihydro isoxazol-5-yl)methyl)-4-oxo-3,4-dihydro-phthalazin-1-yl)-3-methoxyacrylate 

Relevant articles and documents

Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. Current treatments only slow down disease progression, making new therapeutic strategies compelling. Increasing evidence suggests that S1P2 antagonists could be effective agents against fibrotic diseases. Our compound collection was mined for molecules possessing substructure features associated with S1P2 activity. The weakly potent indole hit 6 evolved into a potent phthalazone series, bearing a carboxylic acid, with the aid of a homology model. Suboptimal pharmacokinetics of a benzimidazole subseries were improved by modifications targeting potential interactions with transporters, based on concepts deriving from the extended clearance classification system (ECCS). Scaffold hopping, as a part of a chemical enablement strategy, permitted the rapid exploration of the position adjacent to the carboxylic acid. Compound 38, with good pharmacokinetics and in vitro potency, was efficacious at 10 mg/kg BID in three different in vivo mouse models of fibrotic diseases in a therapeutic setting.

Synthesis, antimicrobial and cytotoxicity studies of some novel modified strobilurin derivatives

A series of some new 3-isoxazoline substituted methyl-3-methoxy-2-(4-oxo-3, 4-dihydrophthalazin-1-yl)prop-2-enoate derivatives were designed and synthesized from methyl-(4-oxo-3,4-dihydrophthalazin-1-yl)acetate, which in turn was prepared from phthalic anhydride. The structures of synthesized new compounds were characterized by spectral data and studied for their antimicrobial activities and cytotoxicity. Several of these compounds showed good antimicrobial activity.

Benzodiazepine receptor ligands. Synthesis and in vitro binding activity of some 6-substituted-3-aryl-1,2,4-triazolo [3,4-a]phthalazines

-